Synairgen (LON:SNG) Shares Down 0.2% – Here’s What Happened

Synairgen plc (LON:SNG)’s stock price traded down 0.2% during mid-day trading on Monday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02). 478,281 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 2,614,922 shares. The stock had previously closed at GBX 2 ($0.02).

Synairgen Trading Down 12.3 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The business’s 50 day simple moving average is GBX 3.56 and its 200 day simple moving average is GBX 3.94. The stock has a market cap of £3.53 million, a P/E ratio of -58.50 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).